Castle Biosciences Inc CSTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSTL is a good fit for your portfolio.
News
-
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
-
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
-
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
-
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
-
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
-
Castle Biosciences Reports First Quarter 2024 Results
-
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
-
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Trading Information
- Previous Close Price
- $24.22
- Day Range
- $24.18–24.94
- 52-Week Range
- $9.26–26.70
- Bid/Ask
- $23.10 / $25.47
- Market Cap
- $669.20 Mil
- Volume/Avg
- 246,374 / 254,605
Key Statistics
- Price/Earnings (Normalized)
- 72.82
- Price/Sales
- 2.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 638
Comparables
Valuation
Metric
|
CSTL
|
GH
|
MYGN
|
---|---|---|---|
Price/Earnings (Normalized) | 72.82 | — | — |
Price/Book Value | 1.66 | 46.80 | 3.01 |
Price/Sales | 2.61 | 5.07 | 2.77 |
Price/Cash Flow | 24.46 | — | — |
Price/Earnings
CSTL
GH
MYGN
Financial Strength
Metric
|
CSTL
|
GH
|
MYGN
|
---|---|---|---|
Quick Ratio | 8.82 | 6.11 | 1.52 |
Current Ratio | 9.25 | 6.54 | 1.99 |
Interest Coverage | −1,996.48 | −198.43 | −81.03 |
Quick Ratio
CSTL
GH
MYGN
Profitability
Metric
|
CSTL
|
GH
|
MYGN
|
---|---|---|---|
Return on Assets (Normalized) | 2.04% | −17.37% | −1.93% |
Return on Equity (Normalized) | 2.31% | −213.40% | −2.88% |
Return on Invested Capital (Normalized) | 0.02% | −22.39% | −2.33% |
Return on Assets
CSTL
GH
MYGN
Diagnostics & Research Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Yfmcnfph | Yzphh | $227.2 Bil | |
DHR
| Danaher Corp | Zzpcxgtgsp | Mbpnk | $196.9 Bil | |
A
| Agilent Technologies Inc | Vkkhxwthy | Kkjb | $45.2 Bil | |
IDXX
| IDEXX Laboratories Inc | Xdgvqjss | Bwwdszq | $44.9 Bil | |
IQV
| IQVIA Holdings Inc | Mrjjgxvy | Yrflfv | $42.8 Bil | |
MTD
| Mettler-Toledo International Inc | Gdxxldns | Dfsfg | $32.5 Bil | |
ICLR
| Icon PLC | Pxcbfbbh | Vcvvbr | $26.0 Bil | |
WAT
| Waters Corp | Lwhbsszyf | Jbrh | $21.1 Bil | |
LH
| Laboratory Corp of America Holdings | Nvpvgcqb | Npwpc | $17.8 Bil | |
ILMN
| Illumina Inc | Kkcsytlj | Zwwbyhn | $17.7 Bil |